To sum up, IFN-β 1a/b, Dimethyl fumarate and Natalizumab may be effective in the treatment of virus-induced MS by regulating Type I IFN pathway, IL-17, CD4+ and CD8+ T cells. This evidence concerns the gene IL17A and myeloid sarcoma.